Deerfield’s Boulevard Bio pens $1.6B deal for trispecific TCE from China’s Metis TechBio

U.S.-based Boulevard Bio is paying $20 million upfront to China’s Metis TechBio for the global rights to a trispecific T-cell engager for autoimmune diseases.